엑셀세라퓨틱스

373110KOSDAQ기초 의약물질 제조업

50.3 / 100

Reference Date: 2026-06-10

Financial Score11.5 / 40

News Sentiment20.8 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Declined 12.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Excel Therapeutics focuses on the cell culture media market essential for cell and gene therapy (CGT) development, targeting the rapidly growing cell therapy segment, which is projected to expand from $64 billion in 2024 to $306 billion by 2034. The company is diversifying its business into cultivated meat, cosmetics, artificial blood, and other fields, while advancing domestic media production through continuous R&D.

Number of Employees

65people

Average Salary

66.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

3.22Industry Average 1.741.0Point

1.9x industry avg (risky)

ROE

-134.41Industry Average -6.033.5Point

22.3x industry avg (excellent)

Debt Ratio

45.55Industry Average 6.620.0Point

6.9x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲36.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼11.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -157.0% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 83

Positive
K바이오 소재 ‘퍼스트무버’… 세계시장 도전
엑셀세라퓨틱스의 엑소좀 배지 공급계약 체결로 세포·유전자 치료제 시장 성장 기대감 증가.
Positive
엑셀세라퓨틱스, 中 상해세포치료그룹에 배지 공급...22조시장 정조준
엑셀세라퓨틱스의 중국 상해세포치료그룹에 대한 배지 공급 소식은 글로벌 시장 진출 확대를 시사하며 긍정적 영향을 미친다.
Positive
엑셀세라퓨틱스, 일반의약품 사업 본격화…中 알리 헬스 입점
엑셀세라퓨틱스가 중국 알리 헬스 플랫폼에 입점하며 OTC 의약품 수출 사업을 확대함으로써 긍정적인 시장 반응을 이끌어냈다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 1,330Won52-week high 3,34052-week low 1,229

1-month return1.0Point

1m -12.33% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral분기보고서 (2026.03)2026-05-15
Neutral[기재정정]사업보고서 (2025.12)2026-05-15